查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球配製药房市场按产品、配药类型、治疗用途、无菌性和最终用户划分－预测至2030年
市场调查报告书
商品编码
1872634

全球配製药房市场按产品、配药类型、治疗用途、无菌性和最终用户划分－预测至2030年

Compounding Pharmacy Market by Product (Oral, Topical, Parenteral), Compounding Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT), Sterility (Sterile), End User (Pediatric, Adult) - Global forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 305 Pages | 订单完成后即时交付

价格

全球药局市场预计将从 2025 年的 147.2 亿美元成长到 2030 年的 194.1 亿美元，2025 年至 2030 年的复合年增长率为 5.7%。

市场成长主要受个人化医疗发展趋势的推动。

调查范围
调查期 2022-2030
基准年 2024
预测期 2025-2030
单元 百万/十亿美元
部分 产品、配方类型、治疗用途、无菌性、最终用户
目标区域 北美洲、欧洲、亚太地区、中东和非洲、拉丁美洲

然而，原料药、辅料供应和临床检验/检测能力的限制预计将限制市场成长。

复方药局市场-IMG1

按产品类型划分，口服药物在配製药房市场中占最大份额。

由于对个人化治疗的需求日益增长，口服药物在全球市场占据了重要地位。该领域涵盖多种剂型，例如胶囊、片剂、锭剂、溶液和混悬剂，广泛应用于荷尔蒙补充疗法、儿科和老年护理、疼痛管理、胃肠道治疗以及慢性病管理。复方口服药物使药剂师能够客製化剂量强度、口味、辅料和释放曲线，从而提高患者的用药依从性，特别适用于吞嚥标准片剂困难或需要精确给药的患者。心血管疾病、糖尿病和内分泌疾病等慢性病的日益增多，催生了对能够最大限度提高疗效并减少副作用的个人化口服治疗的需求，进一步推动了该领域的成长。缓释系统、掩遮罩技术和生物利用度增强载体等技术创新提高了治疗效果和病患体验。遵守FDA法规和USP标准可确保安全性、无菌性和质量，从而建立医疗服务提供者和患者之间的信任。口服药物持续推动收入成长，这得益于人们对个人化医疗日益增长的关注，以及医院、专科诊所和零售药局等管道的供应不断增加。凭藉其便利性、个人化和高效治疗的特点，该领域在全球整体药房市场的发展中发挥关键作用。

到2024年，疼痛管理领域将占据治疗用途领域的最大份额。

在全球范围内，肌肉骨骼疾病、神经病变和术后疼痛等急性及慢性疼痛的流行，使得疼痛管理领域在按治疗应用分類的药品市场中占据最大份额。关节炎、下背痛、癌症相关疼痛和偏头痛发病率的上升，推动了对有效镇痛疗法的需求，包括非类固醇消炎剂（NSAIDs）、鸦片类药物、局部镇痛药和联合疗法。个人化疼痛管理方案的日益普及，例如缓释缓释性和标靶化给药系统，提高了疗效并减少了全身性副作用，进一步提高了患者依从性并促进了市场成长。经皮吸收贴片和局部注射疗法等技术进步，拓展了治疗选择，让患者的长期疼痛管理更加便利。良好的医疗覆盖范围、人们对疼痛作为重要健康问题的认识不断提高以及老年人口的增长，都为该领域的持续增长提供了支持。领先的製药公司正透过研发新型镇痛药、生物製药和非阿片类替代药物来强化产品系列，旨在占据更大的市场份额。随着对安全、有效且以患者为中心的疼痛管理解决方案的需求持续增长，预计该治疗领域将继续保持主导地位，这反映了已开发市场和新兴市场持续的创新和收入成长。

2025-2030年间，北美将在全球药局市场占据最大的市场份额。

以美国主导的北美地区继续在全球配製药房市场占据主导地位。该地区的领先地位与其强大的医疗保健基础设施、严格的监管标准以及503A/503B配製药房的广泛分布密切相关。这些药局在提供个人化药物方面发挥着至关重要的作用，尤其是在市售药物疗效不足的情况下。美国市场提供种类繁多的配製药品，包括口服药物、外用药物和无菌製剂，以满足各种不同的治疗需求。近年来，对特殊配製药品的需求不断增长，尤其是在疼痛管理、荷尔蒙补充疗法和儿科护理领域。美国食品药物管理局（FDA）等监管机构持续监测并确保配製药品的安全性和有效性，从而在医疗保健系统中建立信任。这些因素共同凸显了北美在扩大和改善配製药房服务可及性方面的重要作用。

本报告分析了全球配药药房市场，提供了关键驱动因素和限制因素、竞争格局和未来趋势的资讯。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 主要发现

  • 配药药房市场概览
  • 北美药局市场按产品和国家划分（2025 年）
  • 药局市场：地域成长机会
  • 药局市场：新兴市场与已开发市场
  • 相互关联的市场与跨产业机会
  • 新的经营模式和生态系统变化
  • 创投/私募股权投资趋势及新创Start-Ups现状
  • 监理政策倡议

第五章 市场概览

  • 介绍
  • 市场动态
    • 司机
    • 抑制因素
    • 机会
    • 任务
  • 波特五力分析
  • 主要相关利益者和采购标准
  • 总体经济指标
    • 医疗成本趋势
    • 全球癌症负担
    • 药物研发的影响
  • 价值链分析
  • 生态系分析
  • 定价分析
    • 主要企业配药产品参考价格分析（2024 年）
    • 2024年各地区药局产品定价分析
  • 重大会议和活动（2025-2026）
  • 影响客户业务的趋势/颠覆性因素
  • 投资和资金筹措方案
  • 技术分析
    • 主要技术
    • 互补技术
    • 邻近技术
  • 人工智慧/生成式人工智慧对药局市场的影响
  • 监管分析
    • 区域监管机构、政府机构和其他组织
    • 法规结构
  • 2025年美国关税对药品市场的影响
    • 介绍
    • 主要关税税率
    • 价格影响分析
    • 对国家的影响
    • 对製造业的影响
  • 未满足的需求和閒置频段

第六章：按产品分類的配药药房市场

  • 介绍
  • 口服药物
  • 外用药物
  • 注射用药
  • 眼科药物
  • 鼻腔药物
  • 直肠给药
  • 其他产品

第七章：依配药类型分類的配药药局市场

  • 介绍
  • 药物剂量变化
  • 药物成分的变化
  • 目前製药生产无法进行

第八章：依治疗用途分類的配药药房市场

  • 介绍
  • 疼痛管理
  • 荷尔蒙补充疗法
  • 皮肤病
  • 营养补充品
  • 其他治疗用途

9. 药局市场：无菌性

  • 介绍
  • 无菌
  • 非无菌

第十章：按最终用户分類的配药药房市场

  • 介绍
  • 成人
  • 老年患者
  • 儿科患者

第十一章：各地区的配药药房市场

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东和非洲
    • 中东和非洲宏观经济展望
    • 海湾合作委员会国家
    • 其他中东和非洲地区

第十二章 竞争格局

  • 介绍
  • 主要参与企业的策略/优势
  • 收入分析（2022-2024）
  • 市占率分析（2024 年）
  • 企业评估矩阵：主要企业（2024）
  • 公司评估矩阵：Start-Ups/中小企业（2024 年）
  • 公司估值和财务指标
  • 品牌/产品对比
  • 竞争场景

第十三章：公司简介

  • 主要企业
    • BAXTER
    • EMPOWER PHARMACY
    • B. BRAUN SE
    • FAGRON
    • QUVA PHARMA, INC.
    • SCA PHARMA
    • NEPHRON PHARMACEUTICALS
    • LEITERS HEALTH
    • ICON GROUP
    • ROSEWAY LABS
    • ITH PHARMA
    • PENCOL COMPOUNDING PHARMACY
    • FORMUL8
    • AURORA COMPOUNDING PHARMACY
  • 其他公司
    • CUSTOM MED APOTHECARY
    • INSTITUTIONAL PHARMACY SOLUTIONS
    • FUSION APOTHECARY
    • INNOVATION COMPOUNDING PHARMACY
    • RX3 COMPOUNDING PHARMACY
    • DOUGHERTY'S PHARMACY, INC.
    • LORRAINE'S PHARMACY
    • WELLS PHARMA
    • OLYMPIA PHARMACY
    • FRESH THERAPEUTICS
    • MEDIOS AG

第十四章附录

Product Code: PH 9569

The global compounding pharmacy market is projected to reach USD 19.41 billion by 2030 from an estimated USD 14.72 billion in 2025, at a CAGR of 5.7% from 2025 to 2030. The market's growth has mainly been driven by the increasing trend toward personalized doses.

Scope of the Report
Years Considered for the Study2022-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD) Million/Billion
Segmentsby Product (Oral, Topical, Parenteral), Compounding Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT), Sterility (Sterile), End User (Pediatric, Adult)
Regions coveredNorth America, Europe, Asia Pacific, Middle East & Africa, and Latin America

However, capacity constraints in API, excipient supply, and CCI/testing are expected to limit the market.

Compounding Pharmacy Market - IMG1

The oral drugs held the highest share in the compounding pharmacy market by product type.

The compounding pharmacy market is segmented by product type into topical drugs, oral drugs, parenteral drugs, rectal drugs, nasal drugs, ophthalmic drugs, and other products. Among these, the oral drugs segment holds a key position in the global market, driven by the increasing need for personalized therapies tailored to individual patient requirements. This segment includes a wide variety of formulations such as capsules, tablets, lozenges, solutions, and suspensions, which are extensively used in hormone replacement therapy, pediatric and geriatric care, pain management, gastrointestinal treatments, and chronic disease management. Compounded oral medications enable pharmacists to customize dosage strengths, flavors, excipients, and release profiles, thereby improving patient compliance-especially among those who have difficulty swallowing standard tablets or who need precise dosing. The rising prevalence of chronic conditions like cardiovascular diseases, diabetes, and endocrine disorders further fuels this segment's growth by creating demand for personalized oral treatments that maximize efficacy and reduce side effects. Technological innovations, including sustained-release systems, taste-masking techniques, and bioavailability-enhancing carriers, improve therapeutic performance and patient experience. Adherence to FDA regulations and USP standards ensures safety, sterility, and quality, building confidence among healthcare providers and patients. Along with the growing emphasis on personalized medicine and increased availability through hospitals, specialty clinics, and retail pharmacies, oral drugs continue to be a major driver of revenue growth. The segment's focus on convenience, customization, and effective therapy highlights its vital role in the overall development of the global compounding pharmacy market.

The pain management segment reported the highest share of the therapeutic application segment in 2024

The pain management segment holds the largest share in the pharmaceutical market by therapeutic application, driven by the global prevalence of acute and chronic pain conditions across musculoskeletal, neuropathic, and post-surgical patient groups. Increasing cases of arthritis, back pain, cancer-related pain, and migraines have boosted demand for effective pain relief therapies, including NSAIDs, opioids, topical analgesics, and combination treatments. The rising use of personalized pain management options, such as sustained-release formulations and targeted delivery systems, improves effectiveness while reducing systemic side effects, further increasing patient adherence and market growth. Technological advances, like transdermal patches and localized injectable therapies, have broadened treatment choices and made long-term pain management more convenient for patients. Favorable insurance coverage, greater awareness of pain as a key health issue, and the expanding elderly population support consistent growth in this segment. Leading pharmaceutical firms are enhancing their portfolios through research into new analgesics, biologics, and non-opioid alternatives, positioning themselves to capture larger market shares. As the need for safe, effective, and patient-focused pain management solutions continues to grow, this therapeutic segment is expected to stay dominant, reflecting sustained revenue increases and ongoing innovation in both developed and emerging markets.

North America accounted for the largest market share in the global Compounding pharmacy market from 2025 to 2030.

North America remains the leading region in the global compounding pharmacy market, mainly due to the United States. The region's dominance is linked to its strong healthcare infrastructure, strict regulatory standards, and a large presence of both 503A and 503B compounding pharmacies. These pharmacies are essential in providing personalized medications, especially where commercially available drugs are insufficient. The US market offers a wide variety of compounded products, including oral, topical, and sterile preparations, to meet different therapeutic needs. Recent trends show a rising demand for specialized compounded medications, particularly in pain management, hormone replacement therapy, and pediatric care. Regulatory agencies like the FDA continue to monitor and ensure the safety and effectiveness of compounded drugs, building trust within the healthcare system. This combination of factors highlights North America's key role in advancing and improving access to compounding pharmacy services.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side-70% and Demand Side-30%
  • By Designation: Managers-45%, CXO and Directors-30%, and Executives-25%
  • By Region: North America-40%, Europe-25%, the Asia Pacific-25%, Latin America-5%, and the Middle East & Africa-5%

List of Key Companies Profiled in the Report:

Key players in the Compounding pharmacy market include Baxter (US), Empower Pharmacy (US), B. Braun (Germany), Fagron (Netherlands), QuVa Pharma (US), SCA Pharma (US), Nephron Pharmaceuticals (US), Leiters Health (US), Pharmaxo (UK), Icon Group (Australia), Roseway Labs (UK), ITH Pharma (UK), Pencol Compounding Pharmacy (Canada), Formula 8 (South Africa), and Aurora Compounding Pharmacy (Canada)

Research Coverage:

This research report categorizes the compounding pharmacy market by product (oral, topical, parenteral), compounding type (ingredient alteration, dosage alteration), therapeutic application (pain management, HRT), sterility (sterile), and end user (pediatric, adult). The scope of the report includes detailed information about the main factors affecting the growth of the Compounding pharmacy market, such as drivers, restraints, challenges, and opportunities. It also features an in-depth analysis of key industry players, offering insights into their business overview, products, solutions, strategies, collaborations, partnerships, and agreements. The report covers recent developments like new approvals, launches, collaborations, acquisitions, and other updates related to the Compounding pharmacy market.

Key Benefits of Buying the Report:

The report will assist market leaders and new entrants by providing them with the closest estimates of revenue figures for the entire Compounding pharmacy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop appropriate go-to-market strategies. This report will enable stakeholders to grasp the market's key indicators and offer information on the main market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (Persistent drug shortages in North America and Europe, full enforcement of USP standards, safety push for ready-to-administer and standardized doses, continued demand creating supply gap for GLP-1 drugs, and trend toward personalization of doses), restraints (Resolution of GLP-1 shortages reduces reliance on compounded alternatives, stricter FDA oversight and insanitary conditions enforcement, and limitations on bulk drug substances.), opportunities (Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic & chemo-adjuncts and Radiopharmaceutical compounding standardization), and challenges (Capacity bottlenecks in API, excipient supply, and CCI/testing, and limited quality-system maturity and gaps in stability/BUD evidence generation.) influencing the growth of the market.
  • Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the compounding pharmacy market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the compounding pharmacy market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the Compounding pharmacy market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Objectives of secondary research
      • 2.1.1.2 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
      • 2.1.2.2 Key objectives of primary research
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 GLOBAL MARKET ESTIMATION
      • 2.2.1.1 Company revenue analysis (bottom-up approach)
      • 2.2.1.2 Revenue share analysis
      • 2.2.1.3 MnM repository analysis
      • 2.2.1.4 Primary interviews
    • 2.2.2 INSIGHTS OF PRIMARY EXPERTS
    • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
  • 2.3 MARKET GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

  • 3.1 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
  • 3.2 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
    • 3.2.1 STARTUPS AND INNOVATIVE COMPANIES
    • 3.2.2 ESTABLISHED MARKET LEADERS

4 PREMIUM INSIGHTS

  • 4.1 COMPOUNDING PHARMACY MARKET OVERVIEW
  • 4.2 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT AND COUNTRY (2025)
  • 4.3 COMPOUNDING PHARMACY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 COMPOUNDING PHARMACY MARKET: EMERGING VS. DEVELOPED MARKETS
  • 4.5 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.6 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
  • 4.7 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
  • 4.8 REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Persistent drug shortages in North America and Europe
      • 5.2.1.2 Enforcement of USP standards
      • 5.2.1.3 Push for ready-to-administer (RTA) and standardized doses
      • 5.2.1.4 Continued demand-supply gap for GLP-1 drugs
      • 5.2.1.5 Trend towards personalization of doses
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Resolution of GLP-1 shortages and reduced reliance on compounded alternatives
      • 5.2.2.2 Stricter FDA oversight and intensified enforcement of unsanitary conditions violations
      • 5.2.2.3 Limitations on bulk drug substances
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic, and chemo-adjuncts
      • 5.2.3.2 Radiopharmaceutical compounding standardization
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Capacity bottlenecks in API, excipient supply, and critical compounding infrastructure testing
      • 5.2.4.2 Limited quality-system maturity and gaps in stability/BUD evidence generation
  • 5.3 PORTER'S FIVE FORCES ANALYSIS
    • 5.3.1 THREAT OF NEW ENTRANTS
    • 5.3.2 THREAT OF SUBSTITUTES
    • 5.3.3 BARGAINING POWER OF SUPPLIERS
    • 5.3.4 BARGAINING POWER OF BUYERS
    • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.4 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.4.2 KEY BUYING CRITERIA
  • 5.5 MACROECONOMICS INDICATORS
    • 5.5.1 HEALTHCARE EXPENDITURE TRENDS
    • 5.5.2 GLOBAL CANCER BURDEN
    • 5.5.3 IMPACT OF PHARMA R&D
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • 5.7.1 ROLE IN ECOSYSTEM
  • 5.8 PRICING ANALYSIS
    • 5.8.1 INDICATIVE PRICING ANALYSIS OF COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2024
    • 5.8.2 INDICATIVE PRICING ANAYLSIS OF COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2024
  • 5.9 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.11 INVESTMENT & FUNDING SCENARIO
  • 5.12 TECHNOLOGY ANALYSIS
    • 5.12.1 KEY TECHNOLOGIES
      • 5.12.1.1 Automated compounding devices
      • 5.12.1.2 Sterile compounding equipment
    • 5.12.2 COMPLEMENTARY TECHNOLOGIES
      • 5.12.2.1 Quality control & testing systems
      • 5.12.2.2 Pharmacy information management software (PIMS)
    • 5.12.3 ADJACENT TECHNOLOGIES
      • 5.12.3.1 3D printing of pharmaceuticals
      • 5.12.3.2 Personalized medicine platforms
  • 5.13 IMPACT OF AI/GEN AI ON COMPOUNDING PHARMACY MARKET
  • 5.14 REGULATORY ANALYSIS
    • 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
    • 5.14.2 REGULATORY FRAMEWORK
  • 5.15 IMPACT OF 2025 US TARIFF ON COMPOUNDING PHARMACY MARKET
    • 5.15.1 INTRODUCTION
    • 5.15.2 KEY TARIFF RATES
    • 5.15.3 PRICE IMPACT ANALYSIS
    • 5.15.4 IMPACT ON COUNTRY/REGION
      • 5.15.4.1 US
      • 5.15.4.2 Europe
      • 5.15.4.3 Asia Pacific
      • 5.15.4.4 Rest of the World
    • 5.15.5 IMPACT ON MANUFACTURING INDUSTRIES
  • 5.16 UNMET NEEDS & WHITE SPACES

6 COMPOUNDING PHARMACY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 ORAL DRUGS
    • 6.2.1 INCREASING DEMAND FOR PRECISE AND CUSTOMIZABLE ORAL FORMULATIONS IN UNMET PATIENT POPULATIONS TO DRIVE MARKET
  • 6.3 TOPICAL DRUGS
    • 6.3.1 RISING DEMAND FOR PERSONALIZED TOPICAL TREATMENTS AND ADVANCED DELIVERY VEHICLES TO FUEL MARKET GROWTH
  • 6.4 PARENTERAL DRUGS
    • 6.4.1 RISING DEMAND FOR STERILE INJECTABLE THERAPIES AND SUPPLY-CHAIN DISRUPTIONS TO BOOST MARKET GROWTH
  • 6.5 OPTHALMIC DRUGS
    • 6.5.1 RISING CASES OF EYE-RELATED DISORDERS TO ACCELERATE MARKET GROWTH
  • 6.6 NASAL DRUGS
    • 6.6.1 ADVANCEMENTS IN NASAL DRUG DELIVERY SYSTEMS AND FAVORABLE REGULATORY POLICIES TO PROPEL MARKET GROWTH
  • 6.7 RECTAL DRUGS
    • 6.7.1 PERSONALIZED FORMULATIONS AND REGULATORY SUPPORT TO DRIVE GROWTH IN RECTAL COMPOUNDING THERAPIES
  • 6.8 OTHER PRODUCTS

7 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE

  • 7.1 INTRODUCTION
  • 7.2 PHARMACEUTICAL DOSAGE ALTERATION
    • 7.2.1 TAILORED DOSAGE FORMS TO ENHANCE PATIENT ADHERENCE AND CUSTOMIZATION IN COMPOUNDED MEDICATIONS
  • 7.3 PHARMACEUTICAL INGREDIENTS ALTERATION
    • 7.3.1 INCREASED NEED FOR CUSTOMIZED PHARMACEUTICAL INGREDIENTS TO ENHANCE PATIENT-CENTRIC COMPOUNDING SOLUTIONS
  • 7.4 CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING
    • 7.4.1 PERSISTENT GLOBAL DRUG SHORTAGES AND LIMITATIONS OF LARGE-SCALE PHARMACEUTICAL PRODUCTION TO PROPEL ADOPTION

8 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 PAIN MANAGEMENT
    • 8.2.1 NEED FOR PERSONALIZED PAIN RELIEF SOLUTIONS FOR CHRONIC AILMENTS TO SUPPORT MARKET
  • 8.3 HORMONE REPLACEMENT THERAPIES
    • 8.3.1 POPULARITY OF PERSONALIZED HORMONE THERAPIES TO DRIVE STEADY GROWTH IN GLOBAL COMPOUNDING PHARMACY MARKET
  • 8.4 DERMAL DISORDERS
    • 8.4.1 CUSTOMIZED DERMATOLOGICAL SOLUTIONS TO PROPEL GLOBAL COMPOUNDING PHARMACY MARKET EXPANSION
  • 8.5 NUTRITIONAL SUPPLEMENTS
    • 8.5.1 PERSONALIZED NUTRACEUTICALS TO OFFER NICHE BUT BETTER GROWTH OPPORTUNITIES IN COMPOUNDING PHARMACIES
  • 8.6 OTHER THERAPEUTIC APPLICATIONS

9 COMPOUNDING PHARMACY MARKET, BY STERILITY

  • 9.1 INTRODUCTION
  • 9.2 STERILE
    • 9.2.1 RTU/RTA STERILE PREPARATIONS AND OPHTHALMIC PACKS TO DRIVE RAPID GROWTH IN COMPOUNDING PHARMACIES
  • 9.3 NON-STERILE
    • 9.3.1 503A/MAGISTRAL NON-STERILE PREPARATIONS TO DRIVE GLOBAL VOLUME AND VALUE LEADERSHIP IN COMPOUNDING PHARMACIES

10 COMPOUNDING PHARMACY MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 ADULTS
    • 10.2.1 RISING CHRONIC DISEASE BURDEN AND PERSONALIZED THERAPIES TO AUGMENT ADULT SEGMENT GROWTH
  • 10.3 GERIATRIC PATIENTS
    • 10.3.1 AGING DEMOGRAPHICS AND DOSE-FORM CUSTOMIZATION TO PROPEL GERIATRIC SEGMENT GROWTH
  • 10.4 PEDIATRIC PATIENTS
    • 10.4.1 CUSTOMIZED DOSAGE FORMS AND PEDIATRIC-SPECIFIC NEEDS TO DRIVE GROWTH

11 COMPOUNDING PHARMACY MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 US to dominate North American compounding pharmacy market during forecast period
    • 11.2.3 CANADA
      • 11.2.3.1 Personalized treatments, regulatory reinforcement, and supply-gap filling to fuel global compounding pharmacy growth
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Aging demographics, technological advancements, and supportive regulations to drive market
    • 11.3.3 UK
      • 11.3.3.1 Personalized treatments, chronic disease management, and regulatory support to support market growth
    • 11.3.4 FRANCE
      • 11.3.4.1 Focus on chronic disease management to fuel growth in French compounding pharmacy market
    • 11.3.5 ITALY
      • 11.3.5.1 Rising commercial drug development pipeline to spur market growth
    • 11.3.6 SPAIN
      • 11.3.6.1 Global regulatory advancements and rising R&D activities to drive market
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 CHINA
      • 11.4.2.1 Low manufacturing cost and high demand for medicines to favor market growth
    • 11.4.3 JAPAN
      • 11.4.3.1 Increasing prevalence of chronic diseases and growing geriatric population to fuel demand for customized medications
    • 11.4.4 INDIA
      • 11.4.4.1 Increasing pharma R&D activities to support market growth
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Innovation in clinical practice and regulatory support to accelerate compounding pharmacy growth
    • 11.4.6 SOUTH KOREA
      • 11.4.6.1 Regulatory innovation and automation to fuel South Korean compounding pharmacy market growth
    • 11.4.7 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Growing pharmacy & biologics manufacturing sectors and rising R&D sepnding to drive market
    • 11.5.3 MEXICO
      • 11.5.3.1 Regulatory improvements, high cancer rates, and robust pharmaceutical industry to boost market growth
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Rising demand for biologics and increasing prevalence of non-communicable diseases to propel market growth
    • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2023-2025
  • 12.3 REVENUE ANALYSIS, 2022-2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2024
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Region footprint
      • 12.5.5.3 Product footprint
      • 12.5.5.4 Therapeutic application footprint
      • 12.5.5.5 Sterility footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 12.6.5.1 Detailed list of key startup/SMEs
      • 12.6.5.2 Competitive benchmarking of key startups/SMEs
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    • 12.7.1 FINANCIAL METRICS
    • 12.7.2 COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 BAXTER
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Product launches
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Key strengths
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses & competitive threats
    • 13.1.2 EMPOWER PHARMACY
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Expansions
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Key strengths
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 B. BRAUN SE
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product launches
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Key strengths
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses & competitive threats
    • 13.1.4 FAGRON
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Key strengths
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses & competitive threats
    • 13.1.5 QUVA PHARMA, INC.
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 MnM view
        • 13.1.5.3.1 Key strengths
        • 13.1.5.3.2 Strategic choices
        • 13.1.5.3.3 Weaknesses & competitive threats
    • 13.1.6 SCA PHARMA
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Deals
    • 13.1.7 NEPHRON PHARMACEUTICALS
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Expansions
    • 13.1.8 LEITERS HEALTH
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Expansions
    • 13.1.9 ICON GROUP
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Deals
    • 13.1.10 ROSEWAY LABS
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
      • 13.1.10.3 Recent developments
        • 13.1.10.3.1 Other developments
    • 13.1.11 ITH PHARMA
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products offered
    • 13.1.12 PENCOL COMPOUNDING PHARMACY
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
    • 13.1.13 FORMUL8
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products offered
    • 13.1.14 AURORA COMPOUNDING PHARMACY
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products offered
  • 13.2 OTHER PLAYERS
    • 13.2.1 CUSTOM MED APOTHECARY
    • 13.2.2 INSTITUTIONAL PHARMACY SOLUTIONS
    • 13.2.3 FUSION APOTHECARY
    • 13.2.4 INNOVATION COMPOUNDING PHARMACY
    • 13.2.5 RX3 COMPOUNDING PHARMACY
    • 13.2.6 DOUGHERTY'S PHARMACY, INC.
    • 13.2.7 LORRAINE'S PHARMACY
    • 13.2.8 WELLS PHARMA
    • 13.2.9 OLYMPIA PHARMACY
    • 13.2.10 FRESH THERAPEUTICS
    • 13.2.11 MEDIOS AG

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 COMPOUNDING PHARMACY MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
  • TABLE 3 COMPOUNDING PHARMACY MARKET: RISK ANALYSIS
  • TABLE 4 COMPOUNDING PHARMACY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 5 COMPOUNDING PHARMACY MARKET: PORTER'S FIVE FORCES
  • TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPOUNDING PHARMACY PRODUCTS (%)
  • TABLE 7 KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER
  • TABLE 8 HEALTH EXPENDITURE AND FINANCING, 2015-2024 (% OF GDP)
  • TABLE 9 US: CANCER INCIDENCE, BY STATE (2024)
  • TABLE 10 COMPOUNDING PHARMACY MARKET: ROLE IN ECOSYSTEM
  • TABLE 11 INDICATIVE PRICING ANALYSIS COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2024
  • TABLE 12 INDICATIVE PRICING ANAYLSIS OF COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2024
  • TABLE 13 COMPOUNDING PHARMACY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
  • TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 COUNTRY-WISE REGULATORY SCENARIO FOR COMPOUNDING PHARMACIES
  • TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 20 COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 21 COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 22 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 23 EUROPE: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 24 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 25 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 26 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 27 COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 28 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 29 EUROPE: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 31 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 32 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 33 COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 34 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 EUROPE: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 37 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 38 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 39 COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 40 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 EUROPE: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 44 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 45 COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 46 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 47 EUROPE: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 49 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 50 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 51 COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 52 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 53 EUROPE: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 56 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 57 COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 58 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59 EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 63 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 64 COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 69 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 70 COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 71 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 74 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 75 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 76 COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 77 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 78 EUROPE: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 81 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 82 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 83 COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 84 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 EUROPE: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 88 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 89 COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 90 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 91 EUROPE: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 93 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 94 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 95 COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 EUROPE: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 99 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 100 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 101 COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 102 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 103 EUROPE: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 105 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 106 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 107 COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 108 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 109 EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 111 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 113 COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 114 STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 115 NORTH AMERICA: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 116 EUROPE: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 118 LATIN AMERICA: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 MIDDLE EAST & AFRICA: STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 120 NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 121 NORTH AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 122 EUROPE: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 124 LATIN AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 125 MIDDLE EAST & AFRICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 126 COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 127 COMPOUNDING PHARMACY MARKET FOR ADULTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 128 NORTH AMERICA: COMPOUNDING PHARMACY MARKET ADULTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 129 EUROPE: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 131 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 132 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 133 COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 134 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 135 EUROPE: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 137 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 138 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 139 COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 140 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 141 EUROPE: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 142 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 143 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 144 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 145 COMPOUNDING PHARMACY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 146 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 147 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 148 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 149 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 150 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 151 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 152 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 153 US: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 154 US: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 155 US: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 156 US: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 157 US: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 158 CANADA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 159 CANADA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 160 CANADA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 161 CANADA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 162 CANADA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 163 EUROPE: KEY MACROINDICATORS
  • TABLE 164 EUROPE: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 165 EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 166 EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 167 EUROPE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 168 EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 169 EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 170 GERMANY: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 171 GERMANY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 172 GERMANY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 173 GERMANY: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 174 GERMANY: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 175 UK: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 176 UK: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 177 UK: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 178 UK: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 179 UK: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 180 FRANCE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 181 FRANCE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 182 FRANCE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 183 FRANCE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 184 FRANCE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 185 ITALY: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 186 ITALY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 187 ITALY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 188 ITALY: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 189 ITALY: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 190 SPAIN: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 191 SPAIN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 192 SPAIN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 193 SPAIN: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 194 SPAIN: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 195 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 196 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 197 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 198 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 199 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 200 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 201 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 203 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 204 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 207 CHINA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 208 CHINA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 209 CHINA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 210 CHINA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 211 CHINA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 212 JAPAN: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 213 JAPAN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 214 JAPAN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 215 JAPAN: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 216 JAPAN: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 217 INDIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 218 INDIA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 219 INDIA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 220 INDIA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 221 INDIA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 222 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 223 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 224 AUSTRALIA : COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 225 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 226 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 227 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 228 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 229 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 230 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 231 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 232 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 233 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 234 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 235 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 236 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 237 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 238 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 239 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 240 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 241 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 242 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 243 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 244 BRAZIL: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 245 BRAZIL: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 246 BRAZIL: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 247 BRAZIL: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 248 BRAZIL: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 249 MEXICO: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 250 MEXICO: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 251 MEXICO: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 252 MEXICO: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 253 MEXICO: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 254 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 255 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 256 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 257 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 258 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 259 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
  • TABLE 260 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 261 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 262 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 263 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 264 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 265 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 266 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 267 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 268 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 269 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 270 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 271 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 272 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023-2030 (USD MILLION)
  • TABLE 273 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 274 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023-2030 (USD MILLION)
  • TABLE 275 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 276 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2023-2025
  • TABLE 277 COMPOUNDING PHARMACY MARKET: DEGREE OF COMPETITION
  • TABLE 278 COMPOUNDING PHARMACY MARKET: REGION FOOTPRINT
  • TABLE 279 COMPOUNDING PHARMACY MARKET: PRODUCT FOOTPRINT
  • TABLE 280 COMPOUNDING PHARMACY MARKET: THERAPEUTIC APPLICATION FOOTPRINT
  • TABLE 281 COMPOUNDING PHARMACY MARKET: STERILITY FOOTPRINT
  • TABLE 282 COMPOUNDING PHARMACY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 283 COMPOUNDING PHARMACY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT, THERAPEUTIC APPLICATION, AND REGION, 2024
  • TABLE 284 COMPOUNDING PHARMACY MARKET: PRODUCT LAUNCHES, JANUARY 2022-OCTOBER 2025
  • TABLE 285 COMPOUNDING PHARMACY MARKET: DEALS, JANUARY 2022-OCTOBER 2025
  • TABLE 286 COMPOUNDING PHARMACY MARKET: EXPANSIONS, JANUARY 2022-OCTOBER 2025
  • TABLE 287 BAXTER: COMPANY OVERVIEW
  • TABLE 288 BAXTER: PRODUCTS OFFERED
  • TABLE 289 BAXTER: PRODUCT LAUNCHES, JANUARY 2022-OCTOBER 2025
  • TABLE 290 EMPOWER PHARMACY: COMPANY OVERVIEW
  • TABLE 291 EMPOWER PHARMACY: PRODUCTS OFFERED
  • TABLE 292 EMPOWER PHARMACY: EXPANSIONS, JANUARY 2022-OCTOBER 2025
  • TABLE 293 B. BRAUN SE: COMPANY OVERVIEW
  • TABLE 294 B. BRAUN SE: PRODUCTS OFFERED
  • TABLE 295 B. BRAUN SE: PRODUCT LAUNCHES, JANUARY 2022-OCTOBER 2025
  • TABLE 296 FAGRON: COMPANY OVERVIEW
  • TABLE 297 FAGRON: PRODUCTS OFFERED
  • TABLE 298 FAGRON: DEALS, JANUARY 2022-OCTOBER 2025
  • TABLE 299 QUVA PHARMA, INC.: COMPANY OVERVIEW
  • TABLE 300 QUVA PHARMA, INC.: PRODUCTS OFFERED
  • TABLE 301 SCA PHARMA: COMPANY OVERVIEW
  • TABLE 302 SCA PHARMA: PRODUCTS OFFERED
  • TABLE 303 SCA PHARMA: DEALS, JANUARY 2022-OCTOBER 2025
  • TABLE 304 NEPHRON PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 305 NEPHRON PHARMACEUTICALS: PRODUCTS OFFERED
  • TABLE 306 NEPHRON PHARMACEUTICALS: EXPANSIONS, JANUARY 2022-OCTOBER 2025
  • TABLE 307 LEITERS HEALTH: COMPANY OVERVIEW
  • TABLE 308 LEITERS HEALTH: PRODUCTS OFFERED
  • TABLE 309 LEITERS HEALTH: EXPANSIONS, JANUARY 2022-OCTOBER 2025
  • TABLE 310 ICON GROUP: COMPANY OVERVIEW
  • TABLE 311 ICON GROUP: PRODUCTS OFFERED
  • TABLE 312 ICON GROUP: DEALS, JANUARY 2022-OCTOBER 2025
  • TABLE 313 ROSEWAY LABS: COMPANY OVERVIEW
  • TABLE 314 ROSEWAY LABS: PRODUCTS OFFERED
  • TABLE 315 ROSEWAY LABS: OTHER DEVELOPMENTS, JANUARY 2022-OCTOBER 2025
  • TABLE 316 ITH PHARMA: COMPANY OVERVIEW
  • TABLE 317 ITH PHARMA: PRODUCTS OFFERED
  • TABLE 318 PENCOL COMPOUNDING PHARMACY: COMPANY OVERVIEW
  • TABLE 319 PENCOL COMPOUNDING PHARMACY: PRODUCTS OFFERED
  • TABLE 320 FORMUL8: COMPANY OVERVIEW
  • TABLE 321 FORMUL8: PRODUCTS OFFERED
  • TABLE 322 AURORA COMPOUNDING PHARMACY: COMPANY OVERVIEW
  • TABLE 323 AURORA COMPOUNDING PHARMACY: PRODUCTS OFFERED
  • TABLE 324 CUSTOM MED APOTHECARY: COMPANY OVERVIEW
  • TABLE 325 INSTITUTIONAL PHARMACY SOLUTIONS: COMPANY OVERVIEW
  • TABLE 326 FUSION APOTHECARY: COMPANY OVERVIEW
  • TABLE 327 INNOVATION COMPOUNDING PHARMACY: COMPANY OVERVIEW
  • TABLE 328 RX3 COMPOUNDING PHARMACY: COMPANY OVERVIEW
  • TABLE 329 DOUGHERTY'S PHARMACY, INC.: COMPANY OVERVIEW
  • TABLE 330 LORRAINE'S PHARMACY: COMPANY OVERVIEW
  • TABLE 331 WELLS PHARMA: COMPANY OVERVIEW
  • TABLE 332 OLYMPIA PHARMACY: COMPANY OVERVIEW
  • TABLE 333 FRESH THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 334 MEDIOS AG: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 COMPOUNDING PHARMACY MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 COMPOUNDING PHARMACY MARKET: YEARS CONSIDERED
  • FIGURE 3 COMPOUNDING PHARMACY MARKET: RESEARCH DESIGN
  • FIGURE 4 COMPOUNDING PHARMACY MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 COMPOUNDING PHARMACY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 6 COMPOUNDING PHARMACY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)
  • FIGURE 8 REVENUE SHARE ANALYSIS OF BAXTER (2024)
  • FIGURE 9 COMPOUNDING PHARMACY MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 10 COMPOUNDING PHARMACY MARKET: TOP-DOWN APPROACH
  • FIGURE 11 COMPOUNDING PHARMACY MARKET: CAGR PROJECTIONS
  • FIGURE 12 COMPOUNDING PHARMACY MARKET: DATA TRIANGULATION
  • FIGURE 13 COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 COMPOUNDING PHARMACY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 REGIONAL SNAPSHOT OF COMPOUNDING PHARMACY MARKET
  • FIGURE 18 RISING TREND OF PERSONALISED MEDICINES TO PROPEL MARKET GROWTH
  • FIGURE 19 US AND 0RAL DRUGS SEGMENT TO COMMAND LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025
  • FIGURE 20 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD
  • FIGURE 22 COMPOUNDING PHARMACY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 TOTAL PRESCRIPTION DRUG SALES, 2023-2030 (USD BILLION)
  • FIGURE 24 COMPOUNDING PHARMACY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF KEY COMPOUNDING PHARMACY PRODUCTS
  • FIGURE 26 KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER
  • FIGURE 27 GLOBAL PHARMACEUTICAL R&D EXPENDITURE, 2023-2030 (USD BILLION)
  • FIGURE 28 COMPOUNDING PHARMACY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 29 COMPOUNDING PHARMACY MARKET: ECOSYSTEM MAP
  • FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES IN COMPOUNDING PHARMACY MARKET
  • FIGURE 31 INVESTMENT AND NUMBER OF DEALS IN COMPOUNDING PHARMACY MARKET, 2023-2025 (USD MILLION)
  • FIGURE 32 COMPOUNDING PHARMACY MARKET: IMPACT OF AI/GEN AI
  • FIGURE 33 NORTH AMERICA: COMPOUNDING PHARMACY MARKET SNAPSHOT
  • FIGURE 34 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET SNAPSHOT
  • FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2022-2024 (USD MILLION)
  • FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET (2024)
  • FIGURE 37 COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 38 COMPOUNDING PHARMACY MARKET: COMPANY FOOTPRINT
  • FIGURE 39 COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 40 EV/EBITDA OF KEY VENDORS
  • FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 42 COMPOUNDING PHARMACY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 43 BAXTER: COMPANY SNAPSHOT (2024)
  • FIGURE 44 B. BRAUN SE: COMPANY SNAPSHOT (2024)
  • FIGURE 45 FAGRON: COMPANY SNAPSHOT (2024)